Drug profile · INN
dupilumab
DUPIXENT
dupilumab (DUPIXENT) is a interleukin-4 receptor subunit alpha antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — dupilumab
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- INJECTION
- Patents
- 0
- Programs
- 76
- Data quality
- 0.89
Quick answer
dupilumab (DUPIXENT) is a interleukin-4 receptor subunit alpha antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-4 receptor subunit alpha antagonist
Primary target: Interleukin-4 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
This plan frames a Sanofi pipeline pdf-style news brief around 2026 clinical catalysts, with Dupixent as the anchor asset and Lantus as a mature revenue base. It also clarifies the Sanofi Pasteur MSD joint venture structure and why the pipeline matters for analysts and BD teams.
FDA approves Dupixent for COPD with eosinophilic phenotype
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
FDA Approves Dupixent for Eosinophilic Esophagitis Treatment
Dupixent has received FDA approval for the treatment of eosinophilic esophagitis, marking a significant advancement in managing this challenging condition.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dupilumab?
dupilumab (DUPIXENT) is a interleukin-4 receptor subunit alpha antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dupilumab?
DUPIXENT is a marketed brand name for dupilumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dupilumab?
dupilumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.